NCT01249651

To Assess the Efficacy of Esomeprazole 40 mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole

An 8-week, Open Label, Multicentre Study to Assess the Efficacy of Esomeprazole 40 mg Once Daily in Subjects With Continuing Symptoms of Heartburn Following Treatment With a Previous Rabeprazole.

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 101 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

Administration of esomeprazole 40 mg to subjects who still had heartburn after receiving rabeprazole 20 mg once daily for 4 to 8 weeks will result in statistically significant improvement of heartburn after 8-week treatment.

Conditions

• Heartburn

Interventions

Type	Name	Description
DRUG	esomeprazole 40 mg	esomeprazole 40 mg once daily, 8 weeks

Timeline

• Start date: 2010-11-01
• Primary completion: 2011-06-01
• Completion: 2011-06-01
• First posted: 2010-11-30
• Last updated: 2012-10-31
• Results posted: 2012-10-31

Locations

1 site across 1 country: China